Inovio plans human trials for potential Covid-19 vaccine in South Korea in June
[SEOUL] Inovio Pharmaceuticals said on Thursday it plans to begin early human trials of its experimental Covid-19 vaccine in South Korea later in June and partnered with non-profit organisation International Vaccine Institute.
The company said the two-stage trial, conducted in collaboration with Seoul National University Hospital, would assess the safety and effectiveness of the vaccine in 40 healthy adults, and later expand to enroll an additional 120 people.
Inovio, which is among the several companies looking to develop a vaccine to combat the pandemic, is also testing its vaccine in human trials in the United States. The company expects to begin mid-stage trial in mid-summer.
There is currently no approved treatment or vaccine for Covid-19. Experts predict a safe and effective vaccine could take 12 to 18 months to develop. Governments, drugmakers and researchers are working on around 100 vaccine programmes.
REUTERS
GET BT IN YOUR INBOX DAILY
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece
Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom
Swiss watch exports plunge as China and Hong Kong demand dries up
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Billionaires selling cheap stuff get richer from inflation pain
Amazon to push cashierless shopping tech into more third-party stores, while backing off itself